Rasagiline mesylate161735-79-1上海惠诚

10-2315

(1R)-2,3-Dihydro-N-2-propynyl-1H-inden-1-amine methanesulfonate

161735-79-1

C12H13N • CH3SO3H

267.34

50mg

250mg

White solid

98% by TLC NMR (Conforms)

TVP-1012; Azilect

Soluble in DMSO (up to 50 mg/ml), in Water (up to 50 mg/ml), or in Ethanol (up to 30 mg/ml)

-20°C (des.)

Stable for 2 years as supplied. Solutions in DMSO, distilled water or ethanol may be stored at -20°C for up to 1 month.

Rasagiline mesylate (161735-79-1) is a potent, irreversible monoamine oxidase (MAO) inhibitor selective for MAO-B (IC50=4.43 nM) over MAO-A (IC50=412 nM).1Parkinson’s disease therapeutic.2 Displays neuroprotective and neurorestorative properties in a Parkinson’s disease zebrafish model.3 Prevents α-synuclein-induced dopaminergic neuronal death and rescues TrkB neurotrophic signaling.4 Enhances BDNF levels and is neuroprotective in Parkinson’s disease models.5

References/Citations

1) Youdim et al. (2001), Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B; Br. J. Pharmacol., 132 500
2) Cereda et al. (2017), Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case-control study; J. Neurol., 264 1254
3) Cronin and Grealy (2017), Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in Zebrafish 6-Hydrocydopamine Model of Parkinson’s Disease; Neuroscience, 367 34
4) Kang et al. (2017), TrkB neurotropic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson’s disease; Proc. Natl. Acad. Sci. USA, 114 10773
5) Ledreux et al. (2016), BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson’s disease; Brain Res., 1631 34